Objective : To compare the osteogenic differentiation ability of human apical papilla stem cells (SCAPs) , dental pulp mesenchymal stem cells (DPSCs) and alveolar bone mesenchymal stem cells (ABMMSCs) in vitro. Methods : The apical papilla stem cells , dental pulp mesenchymal stem cells and alveolar bone mesenchy⁃ mal stem cells isolated from the third molars and alveolar bone tissues were cultured and passaged. The morphology of primary and P3 generation cells was observed under a microscope. Flow cytometry was used to detect cell immunophenotype. Real⁃time fluorescent quantitative PCR (qRT⁃PCR) and cell counting kit⁃8 were used to analyze cell senescence and proliferation ability. After osteogenic induction , alkaline phosphatase (ALP) and alizarin red staining and qRT⁃PCR were used to detect osteogenic related genes to compare osteogenic ability. Results: There was no significant difference in the morphology of the three cells , which showed the morphology of fibroblasts , long spindle⁃shaped , smooth and uniform after passage. There were no senescence differences among the 3 types of cells , all of which maintained stable proliferative capacity ; the proliferation capacity of SCAPs was significantly higher than that of the other 2 types of cells , and the proliferation capacity of ABMMSCs was weaker; ALP staining and alizarin red staining after 7 and 14 d osteogenesis induction showed that the osteogenic ability of ABMMSCs was significantly stronger than that of SCAPs and DPSCs ; qRT⁃PCR showed that ABMMSCs had the most significant inrease in osteogenesis⁃related genes. Conclusion SCAPs , DPSCs and ABMMSCs have stable biological properti and can undergo osteogenic differentiation , and ABMMSCs have stronger osteogenic ability than DPSCs and SCAPs in vitro.

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.